Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the…
Updated cancer treatment guidelines reflect significant progress in cancer care delivery through ongoing collaborative efforts to strengthen oncology resources across…
AESMED to Focus on Promoting the 1111 Hair Care Day Campaign SEOUL, South Korea, Oct. 28, 2025 /PRNewswire/ -- AESMED…
In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or…
SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…
FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate…
The National Comprehensive Cancer Network expands interactive library of evidence-based, expert consensus-driven cancer care guidance to now cover treatment for…
September 28, 2025 19:30 ET | Source: Biogen Inc. TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai…
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…